drugset / Trial / NCT07259512

Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure

NCT07259512

Phase 4 Recruiting 80 enrolled Evi Liliek Wulandari
RandomizedParallel-groupTriple-blindTreatment

Summary

This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.

Timeline

Start
2025-06-30
Primary completion
2025-12-31
Completion
2026-01-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramipril Small molecule 5 mg
Subject Ramipril Small molecule 10 mg